On January 7, UBS initiated coverage of Pfizer, highlighting its strategic partnership with MTSR in the promising obesity sector. Despite enthusiasm for the deal, the bank maintains a neutral rating on the stock, reflecting caution over near-term outlook. Additionally, Pfizer is noted for its attractive dividend yield exceeding 6%, bolstering its defensive investment profile.

Pfizer is set to release its Q4 results next month, with analysts forecasting a double-digit decline in profits. This announcement may temper market expectations, although the recent daily share price movement remains stable and does not indicate immediate significant concern.

The article highlights a challenging trading session linked to mixed US employment data and uncertainties around Fed policy, broadly impacting the Dow Jones. For Pfizer, which saw a moderate daily decline (-1.16%), this volatility reflects the macroeconomic environment rather than any company-specific trend. Investor reaction appears driven more by the overall economic context than factors unique to the firm.